Zacks Investment Research on MSN
PFE Talzenna combo shows strong efficacy in wider prostate cancer use
Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP ...
Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results